Chinmaya Rath
Corporate Officer/Principal bei GLYCOMIMETICS, INC.
Vermögen: 275 614 $ am 30.04.2024
Profil
Chinmaya Rath is the founder of Cellurx.
He is currently the Director at Catena Biosciences, Inc., the Chief Business Officer & Senior Vice President at GlycoMimetics, Inc., and a Venture Partner at Social Impact Capital, Inc. He holds an MBA from Warwick Business School and an undergraduate degree from Ravenshaw University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
GLYCOMIMETICS, INC.
0,25% | 12.01.2024 | 161 178 ( 0,25% ) | 275 614 $ | 30.04.2024 |
Aktive Positionen von Chinmaya Rath
Unternehmen | Position | Beginn |
---|---|---|
GLYCOMIMETICS, INC. | Corporate Officer/Principal | - |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Direktor/Vorstandsmitglied | - |
Cellurx | Vorstandsvorsitzender | - |
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Private Equity Investor | 01.11.2022 |
Ausbildung von Chinmaya Rath
Warwick Business School | Masters Business Admin |
Ravenshaw University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GLYCOMIMETICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Finance |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
Cellurx |